Rejoy 15 mg (Tablet)

Unit Price: ৳ 10.00 (3 x 10: ৳ 300.00)

Strip Price: ৳ 100.00

Medicine Details

Category	Details
Generic	Mirtazapine
Company	Eskayef pharmaceuticals ltd
Also available as	Rejoy 75 mg tablet Rejoy 30 mg tablet

Rejoy Tablets are indicated for the treatment of major depressive disorder (MDD).
Atypical anti-depressant drugs.
Rejoy has clinically significant drug-drug interactions with Monoamine Oxidase Inhibitors (MAOI) & other serotonergic drugs such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St. John's wort.
Rejoy may interrupt the metabolism or activity of Carbamazepine, Phenytoin or Cimetidine. Patient should avoid Alcohol & Diazepam while taking Rejoy.
Mirtazapine is contraindicated in patients with a known hypersensitivity to Mirtazapine or to any of the excipients.
Pregnancy Category-C. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during Mirtazapine therapy. Patients should be advised to notify their physician if they are breastfeeding an infant.
The most common side effects of Rejoy are dizziness, drowsiness, dry mouth, increased appetite, weight gain etc.
Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down.

The recommended starting dose for Mirtazapine tablets is 15 mg/day, administered in a single dose, preferably in the evening or prior to sleep.
The effective dose range was generally 15 to 45 mg/day and the patients not responding to the initial 15 mg dose may benefit from dose increases up to a 30 mg to maximum of 45 mg/day.
Use in children are not recommended to Mirtazapine.
If anyone misses a dose of mirtazapine, take it as soon as remember unless it is close to when the next dose is due. If anyone missed a dose of medication and it is close to the time of next dose, skip the missed dose and should take next dose at the regularly scheduled time. One should not take double or more than prescribed dose.

The mechanism of action of Mirtazapine as with other drugs effective in the treatment of major depressive disorder is unknown.
Evidence gathered in preclinical studies suggests that Mirtazapine enhances central noradrenergic and serotonergic activity.
Mirtazapine is a potent antagonist of 5-HT2 and 5-HT3 receptors.
Mirtazapine has no significant affinity for the 5-HT1A and 5-HT1B receptors.
Mirtazapine is a moderate peripheral α1-adrenergic antagonist, a property that may explain the occasional orthostatic hypotension reported in association with its use.
Mirtazapine is a moderate antagonist at muscarinic receptors, a property that may explain the relatively low incidence of anticholinergic side effects associated with its use.
After oral administration of Mirtazapine tablets, the active constituent mirtazapine is rapidly and well-absorbed, reaching peak plasma levels after about 2 hours.
Binding of mirtazapine to plasma proteins is approximately 85%.
The mean half-life of elimination is 20-40 hours; (26 hours in males, 37 hours in females).
Mirtazapine displays linear pharmacokinetics within the recommended dose range.
Mirtazapine is extensively metabolized and eliminated via the urine and faeces four days.
Major pathways of biotransformation are demethylation and oxidation followed by conjugation.

Rejoy has clinically significant drug-drug interactions with Monoamine Oxidase Inhibitors (MAOI) & other serotonergic drugs such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St. John's wort.
Rejoy may interrupt the metabolism or activity of Carbamazepine, Phenytoin or Cimetidine. Patient should avoid Alcohol & Diazepam while taking Rejoy.

Mirtazapine is contraindicated in patients with a known hypersensitivity to Mirtazapine or to any of the excipients.
The concomitant use of Mirtazapine and a monoamine oxidase (MAO) inhibitor is contraindicated. Mirtazapine should not be used within 14 days of initiating or discontinuing therapy with a monoamine oxidase inhibitor (MAOI).

The most common side effects of Rejoy are dizziness, drowsiness, dry mouth, increased appetite, weight gain etc.

Pregnancy Category-C. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during Mirtazapine therapy.
Patients should be advised to notify their physician if they are breastfeeding an infant.

Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down.
Patients who are to receive Rejoy should be warned about the risk of developing agranulocytosis.
Rejoy may impair judgment, thinking, and particularly, motor skills, because of its prominent sedative effect.
Clinically significant ALT (SGPT) elevations (≥3 times the upper limit of the normal range) may occur.